Literature DB >> 33381944

Lung Transplantation in Idiopathic Pulmonary Fibrosis: Risk Factors and Outcome.

Moshe Shai Amor1, Dror Rosengarten1, Dorit Shitenberg1, Barak Pertzov1, Yael Shostak1, Mordechai Reuven Kramer1.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) has poor prognosis. Anti-fibrotic treatment has been shown to slow disease progression. Lung transplantation (LTx) offers a survival benefit. The 5-year survival after LTx in IPF is between 40 and 50.
OBJECTIVES: To evaluate which IPF patients have better prognosis following LTx.
METHODS: A retrospective study was conducted with all IPF patients who had undergone LTx in the Rabin Medical Center between 2010 and 2018. We collected data on pre-evaluation of pulmonary function tests, echocardiographic and right heart catherization, and anti-fibrotic treatments. The Kaplan-Meier method was used for survival analysis.
RESULTS: Among148 patients who underwent LTx, 58 were double LTx (DLT) and 90 single LTx (SLT). Mean age was 58.07 ± 9.78 years; 104 males and 44 females. DLT patients had significantly lower survival rates than SLT in the short and medium term after LTx. Patients with saturation above 80% after the 6-minute walk test (6MWT) had higher survival rates. Patients over 65 years of age had a lower survival rates. Those with pulmonary hypertension (PHT) above 30 mmHg had a poorer prognosis with lower survival rates.
CONCLUSIONS: IPF patients with higher mean PHT, older age (> 65 years), and desaturation following 6MWT had lower survival rates following LTx. DLT may decrease survival rate compared to SLT just for the short and medium period of time after LTx. These results may lead to better selection of IPF patient candidates for LTx. Additional studies are warranted for choosing which patients will have better prognosis after LTx.

Entities:  

Year:  2020        PMID: 33381944

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  5 in total

Review 1.  TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review).

Authors:  Zhimin Ye; Yongbin Hu
Journal:  Int J Mol Med       Date:  2021-05-20       Impact factor: 4.101

2.  Does continuation of antifibrotics before lung transplantation influence post-transplant outcomes in patients with idiopathic pulmonary fibrosis?

Authors:  Michael Z L Zhu; Joanna Yilin Huang; David Hongwei Liu; Gregory I Snell
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-01-18

Review 3.  Idiopathic pulmonary fibrosis: Current and future treatment.

Authors:  Daniel S Glass; David Grossfeld; Heather A Renna; Priya Agarwala; Peter Spiegler; Joshua DeLeon; Allison B Reiss
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

Review 4.  Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis.

Authors:  Alejandro Egea-Zorrilla; Laura Vera; Borja Saez; Ana Pardo-Saganta
Journal:  Cells       Date:  2022-08-20       Impact factor: 7.666

Review 5.  Relationship of Exercise Capacity, Physical Function, and Frailty Measures With Clinical Outcomes and Healthcare Utilization in Lung Transplantation: A Scoping Review.

Authors:  Nicholas Bourgeois; Shirin M Shallwani; Fahad S Al-Huda; Sunita Mathur; Charles Poirier; Tania Janaudis-Ferreira
Journal:  Transplant Direct       Date:  2022-10-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.